

RECEIVED *Receipt*

#8

PATENT

MAY 22 2001

Attorney Docket No. 27373/34978A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

FILE COPY

Applicants: Lindquist *et al.*

Serial No.: 09/591,632

Filed: June 9, 2000


For: Recombinant Prion-like Genes  
and Proteins and Materials and  
Methods Comprising Same

Group Art Unit: 1644

Examiner: To be assigned.

) I hereby certify that this paper is being  
) deposited with the United States Postal  
) Service as first class mail, postage prepaid,  
) in an envelope addressed to:  
) Commissioner for Patents, Washington,  
) DC 20231 on this date:

) February 8, 2001

)   
) David A. Gass, Esq.

) Reg. No. 38,153

) Attorney for Applicants

**REQUEST FOR CORRECTED FILING RECEIPT**

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231

Sir:

Attached hereto is a copy of a corrected filing receipt issued by the Patent Office. The applicants respectfully request issuance of a new filing receipt that identifies only six inventors and removing the duplicate name of "JiYan Ma, Chicago, IL". (Jiyan Ma's name should appear only once.)

Respectfully submitted,

MARSHALL, O'TOOLE, GERSTEIN,  
MURRAY & BORUN

By



David A. Gass  
Registration No. 38,153  
Attorneys for Applicants  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

February 8, 2001



## UNITED STATES PATENT AND TRADEMARK OFFICE



RECEIVED

MAY 22 2001

 COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov  
 TECHNICAL CENTER 1600/9900

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/591,632	06/09/2000	1644	942	27373/34978A	9	38	12

Marshall O'Toole Gerstein  
 Murray & Borun  
 800 Sears Tower  
 233 South Wacker Drive  
 Chicago, IL 60606-6402

RECEIVED

FEB 05 2001

MARSHALL O'TOOLE

## CORRECTED FILING RECEIPT



\*OC00000005724873\*

Date Mailed: 02/01/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Susan Lindquist, Chicago, IL ;  
 Liming Li, Chicago, IL ;  
 Jiyan Ma, Chicago, IL ;  
 Jia-Jia Liu, Chicago, IL ;  
 Neal Sondheimer, Chicago, IL ;  
 Thomas Scheibel, Chicago, IL ;

~~Jiyan Ma, Chicago, IL ;~~ [remove]

## Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/138,833 06/09/1999

## Foreign Applications

If Required, Foreign Filing License Granted 08/24/2000

\* SMALL ENTITY \*\*

## Title

Recombinant prion-like genes and proteins and materials and methods comprising same

## Preliminary Class

435



**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
Office of Initial Patent Examination  
Customer Service Center  
Washington, DC 20231